Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The intravenous (IV) route for ibuprofen administration has a faster onset of action as compared to the other routes. IV ibuprofen is preferred for the management of post-operative and acute pain. The demand for ibuprofen has increased due to the side effects of opioid analgesics such as respiratory depression, allergic reactions, sedation, and gastrointestinal events.
The market for IV ibuprofen for pain management is in its nascent stage. The world IV ibuprofen market was valued at $3.6 million in 2015, and is projected to reach $14.2 million by 2022, registering a CAGR of 20% during the forecast period. Advantages associated with IV ibuprofen such as rapid result and targeted drug delivery have resulted in the growth of this market. In 2015, FDA approved IV ibuprofen for pediatric use, due to which the market is expected to register a significant growth during the forecast period. Other factors that affect the market growth significantly include increasing incidence of cancer, cardiovascular ailments, pain, headache, toothache, back pain, arthritis, trauma, and shifting trend towards the use of non-opioids drugs. Factors that would hamper the market growth include side effects associated with IV ibuprofen and lengthy approval process.
The world IV Ibuprofen market is segmented on the basis of indication, age group, and country. By indication, further sub-segments considered in this report include pain/inflammation and fever. The age groups considered are pediatrics and adults. The market is segmented into four countries namely Australia, Canada, South Korea, and the U.S.
Currently, Cumberland Pharmaceuticals Inc., is the only IV ibuprofen manufacturer in the market. The company has collaborated with the local/regional drug manufacturers to target new countries by getting product approvals. The key companies profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc. (acquired by Teligent, Inc.), CSL Limited, Sandor Medicaids Pvt Ltd., PT. Soho Industri Pharmasi, Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., and Laboratorios Valmorca, C.A.
KEY BENEFITS FOR STAKEHOLDERS:
INTRAVENOUS (IV) IBUPROFEN MARKET KEY SEGMENTS:
By Indication
By Age Group
By Country
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond: what to expect by 2027
2.2.1 Moderate scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.4 Government regulations
3.5 Research & Analysis
3.5.1 Clinical trials
3.6 Market dynamics
3.6.1 Drivers
3.6.2 Restraints
3.6.3 Opportunities
CHAPTER 4 WORLD ANALGESICS MARKET, BY AGE GROUP, 2015-2022
4.1 Pediatrics
4.1.1 Market size and forecast
4.2 Adults
4.2.1 Market size and forecast
CHAPTER 5 WORLD ANALGESICS MARKET, BY INDICATION, 2015-2022
5.1 Pain
5.1.1 Market size and forecast
5.2 Fever
5.2.1 Market size and forecast
CHAPTER 6 WORLD ANALGESICS MARKET, BY COUNTRY, 2015-2022
6.1 Market size and forecast for IV ibuprofen
6.2 United States
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast for actual IV ibuprofen
6.3 Canada
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast for actual IV ibuprofen
6.4 Australia
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast for actual IV ibuprofen
6.5 South Korea
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast for actual IV ibuprofen
CHAPTER 7 COMPANY PROFILES
7.1 Cumberland Pharmaceuticals Inc.
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Business performance
7.1.5 Key strategic moves and developments
7.1.6 SWOT analysis
7.2 Alveda Pharmaceuticals, Inc. (Acquired by Teligent, Inc.)
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Business performance
7.2.5 Key strategic moves and developments
7.2.6 SWOT analysis
7.3 CSL Limited
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Business performance
7.3.5 Key strategic moves and developments
7.3.6 SWOT analysis
7.4 Sandor Medicaids Pvt Ltd.
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Business performance
7.4.5 Key strategic moves and developments
7.4.6 SWOT analysis
7.5 PT. Soho Industri Pharmasi
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Business performance
7.5.5 Key strategic moves and developments
7.5.6 SWOT analysis
7.6 Germin MED
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Business performance
7.6.5 Key strategic moves and developments
7.6.6 SWOT analysis
7.7 Grifols S.A.
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Business performance
7.7.5 Key strategic moves and developments
7.7.6 SWOT analysis
7.8 Harbin Gloria Pharmaceuticals Co., Ltd.
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Business performance
7.8.5 Key strategic moves and developments
7.8.6 SWOT analysis
7.9 Al Nabeel International Ltd.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Business performance
7.9.5 Key strategic moves and developments
7.9.6 SWOT analysis
7.10 Laboratorios Valmorca, C.A.
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Business performance
7.10.5 Key strategic moves and developments
List of Figures
FIG. 1 TOP IMPACTING FACTORS, MODERATE SCENARIO (2022-2027)
FIG. 2 TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2022-2027)
FIG. 3 TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2022-2027)
FIG. 4 TOP INVESTMENT POCKETS OF IV IBUPROFEN MARKET BY COUNTRY, 2015-2022
FIG. 5 TOP WINNING STRATEGIES
FIG. 6 IV IBUPROFEN MARKET SHARE ANALYSIS, 2014
FIG. 7 TOP FACTORS IMPACTING WORLD IV IBUPROFEN MARKET, 2015-2022
FIG. 8 REVENUE GENERATED BY CUMBERLAND PHARMACEUTICALS (2012-2014)
FIG. 9 CUMBERLAND PHARMACEUTICALS, %REVENUE, BY PRODUCT, (2014)
FIG. 10 SWOT ANALYSIS OF CUMBERLAND PHARMACEUTICALS
FIG. 11 REVENUE GENERATED BY CSL LIMITED (2013-2015)
FIG. 12 CSL LIMITED, %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 13 CSL LIMITED, % REVENUE, BY GEOGRAPHY (2014)
FIG. 14 SWOT ANALYSIS OF CSL LIMITED
FIG. 15 REVENUE GENERATED BY GRIFOLS S.A. (2012-2014)
FIG. 16 GRIFOLS S.A., %REVENUE, BY BUSINESS SEGMENTS, (2014)
FIG. 17 GRIFOLS S.A., % REVENUE, BY GEOGRAPHY (2014)
FIG. 18 SWOT ANALYSIS OF GRIFOLS S.A.
List of Table
TABLE 1 WORLD IV IBUPROFEN MARKET, MODERATE SCENARIO, BY COUNTRY, 2022 2027 ($MILLION)
TABLE 2 WORLD IV IBUPROFEN MARKET, RAPID GROWTH SCENARIO, BY COUNTRY, 2022 2027 ($MILLION)
TABLE 3 WORLD IV IBUPROFEN MARKET, DIMINISHING GROWTH SCENARIO, BY COUNTRY, 2022 2027 ($MILLION)
TABLE 4 CLINICAL TRIALS - ANALGESICS
TABLE 5 GLOBAL INCIDENCES OF DISEASES
TABLE 6 WORLD IV IBUPROFEN MARKET BY AGE GROUP, 2015-2022 ($MILLION)
TABLE 7 WORLD PEDIATRIC IV IBUPROFEN MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 8 WORLD ADULT IV IBUPROFEN MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 9 WORLD PAIN IV IBUPROFEN MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 10 WORLD FEVER IV IBUPROFEN MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 11 WORLD IV IBUPROFEN MARKET, BY COUNTRY, 2015-2022 ($MILLION)
TABLE 12 UNITED STATES: ACTUAL IV IBUPROFEN MARKET, 20152022 ($MILLION)
TABLE 13 CANADA: ACTUAL IV IBUPROFEN MARKET, 20152022 ($MILLION)
TABLE 14 AUSTRALIA: ACTUAL IV IBUPROFEN MARKET, 20152022 ($MILLION)
TABLE 15 SOUTH KOREA: ACTUAL IV IBUPROFEN MARKET, 20152022 ($MILLION)
TABLE 16 COMPANY SNAPSHOT OF CUMBERLAND PHARMACEUTICALS
TABLE 17 CUMBERLAND PHARMACEUTICALS OPERATING SEGMENTS
TABLE 18 COMPANY SNAPSHOT OF ALVEDA PHARMACEUTICALS, INC.
TABLE 19 ALVEDA PHARMACEUTICALS, INC. OPERATING SEGMENTS
TABLE 20 COMPANY SNAPSHOT OF CSL LIMITED
TABLE 21 CSL LIMITED OPERATING SEGMENTS
TABLE 22 COMPANY SNAPSHOT OF SANDOR MEDICAIDS PVT LTD.
TABLE 23 SANDOR MEDICAIDS PVT LTD. OPERATING SEGMENTS
TABLE 24 COMPANY SNAPSHOT OF PT. SOHO INDUSTRI PHARMASI
TABLE 25 PT. SOHO INDUSTRI PHARMASI OPERATING SEGMENTS
TABLE 26 COMPANY SNAPSHOT OF GERMINMED
TABLE 27 GERMINMED OPERATING SEGMENTS
TABLE 28 COMPANY SNAPSHOT OF GRIFOLS S.A.
TABLE 29 GRIFOLS S.A. OPERATING SEGMENTS
TABLE 30 COMPANY SNAPSHOT OF HARBIN GLORIA PHARMACEUTICALS CO., LTD.
TABLE 31 COMPANY SNAPSHOT OF AL NABEEL INTERNATIONAL LTD.
TABLE 32 AL NABEEL INTERNATIONAL LTD. OPERATING SEGMENTS
TABLE 33 COMPANY SNAPSHOT OF LABORATORIOS VALMORCA
TABLE 34 LABORATORIOS VALMORCA OPERATING SEGMENTS
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
